Clinical TrialMay 13, 2026, 09:27 AM
Polyrizon Signs First Clinical Trial Agreement for NASARIXTM Allergy Blocker
AI Summary
Polyrizon Ltd. announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site in Texas. This agreement marks a significant step towards initiating the clinical program for its NASARIXTM (PL-14) Allergy Blocker. The planned multi-center study will assess the safety, tolerability, and efficacy of the investigational nasal spray in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice (GCP) standards.
Key Highlights
- Polyrizon signed its first Clinical Trial Agreement (CTA) for NASARIXTM (PL-14) Allergy Blocker.
- The agreement is with a U.S.-based clinical research site in Texas specializing in allergy studies.
- This marks a key milestone for initiating the clinical program for NASARIXTM.
- The multi-center study will evaluate the safety, tolerability, and efficacy of the nasal spray.
- NASARIXTM is an investigational intranasal formulation designed to provide a non-pharmacological barrier against allergens.
- The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards.
Price Impact
More from PLRZ